Evidence map›Paper›PMID 42181660›Full record

ArticleJID innovations : skin science from molecules to population health2026

CIT tumor lines: A series of immunogenic murine cutaneous squamous cell carcinoma cell lines derived from chemical carcinogenesis.

Robert Letchworth, Miho Tanaka, Alina A Barnes, Lotus Lum, Savannah Hughes, Grant Schlauderaff, Piyush Chaudhary, Kenneth M Ng, Daphne Superville, Jadyn Leek and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JID innovations : skin science from molecules to population health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Robert LetchworthHuntsman Cancer Institute, University of Utah, USA.
Miho TanakaDepartment of Microbiology and Immunology, University of California, San Francisco, USA.
Alina A BarnesHuntsman Cancer Institute, University of Utah, USA.
Lotus LumDepartment of Microbiology and Immunology, University of California, San Francisco, USA.
Savannah HughesHuntsman Cancer Institute, University of Utah, USA.
Grant SchlauderaffHuntsman Cancer Institute, University of Utah, USA.
Piyush ChaudharyHuntsman Cancer Institute, University of Utah, USA.
Kenneth M NgDepartment of Microbiology and Immunology, University of California, San Francisco, USA.
Daphne SupervilleDepartment of Microbiology and Immunology, University of California, San Francisco, USA.
Jadyn LeekHuntsman Cancer Institute, University of Utah, USA.
Joshua TayHuntsman Cancer Institute, University of Utah, USA.
Corinna Martinez LunaDepartment of Microbiology and Immunology, University of California, San Francisco, USA.
Maria GonzalezDepartment of Microbiology and Immunology, University of California, San Francisco, USA.
Eric SmithDepartment of Pathology, University of Utah, USA.
Dekker C DeaconHuntsman Cancer Institute, University of Utah, USA.
Allie GrossmannEarle A. Chiles Research Institute, Providence Cancer Institute of Oregon, Portland, Oregon, USA.
Melissa Q ReevesHuntsman Cancer Institute, University of Utah, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy is widely used to treat advanced-stage skin cancer, but it is effective for only approximately half of patients with skin cancer. To overcome current barriers, preclinical mouse models that faithfully recapitulate the genetics, mutation burdens, and neoantigen patterns of specific human tumor types are essential. However, while many models exist for melanoma, there are few syngeneic murine models of cutaneous squamous cell carcinoma, which is responsible for nearly as many deaths as melanoma each year. Here, we describe a series of 11 cutaneous squamous cell carcinoma tumor lines, the carcinogen-induced tumor (CIT) lines, syngeneic to the FVB strain, that address this need. The CIT lines were established from skin carcinomas induced by 7,12-dimethylbenzanthracene and 12-O-tetradecanoylphorbol-13-acetate treatment and harbor genetic drivers and mutational burdens that recapitulate key features of cutaneous squamous cell carcinoma. Each CIT line gives rise to tumors with a consistent immune infiltration pattern, ranging from T cell-rich "hot" tumors to T cell-poor "cold" tumors. Hot CIT lines exhibit partial responses to immune checkpoint inhibitors, and we have identified two neoantigens present in an immunotherapy-responsive CIT line. The CIT lines thus provide a valuable series of preclinical models for studying anti-tumor immune responses and developing strategies to improve immunotherapy efficacy in cutaneous squamous cell carcinoma.

Indexed as

Cutaneous squamous cell carcinomaImmune checkpoint inhibitorMouse models of cancerTumor immunologyTumor neoantigen

Identifiers

PMID42181660
PMCPMC13196419

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.